AIM: To determine the impact of educational materials (EMs) on the treatment compliance of postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer. PATIENTS & METHODS: Patients (n = 2757) were randomized to standard aromatase inhibitors (AI) alone (group A) or with EMs (group B) in a global, real-world setting. RESULTS: The 2-year results (n = 2242) showed EMs had no impact on compliance (82 vs. 82%, group A vs. B), compliance with initial AI (82 vs. 81%) or persistence (90 vs. 88%), confirming the 1-year interim analysis (n = 2567). Of the 2082 patients considered compliant at 1 year, 77% remained compliant at 2 years. Discontinuations (9%) were mainly attributed to AI-related side effects (68% of discontinuations). Exploratory analyses suggest a relationship between patient characteristics and compliance behaviors. CONCLUSION: EMs do not improve compliance in this patient population. Compliance and persistence are complex end points influenced by multiple variables. Side effects were the main reasons for discontinuations.
RCT Entities:
AIM: To determine the impact of educational materials (EMs) on the treatment compliance of postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer. PATIENTS & METHODS:Patients (n = 2757) were randomized to standard aromatase inhibitors (AI) alone (group A) or with EMs (group B) in a global, real-world setting. RESULTS: The 2-year results (n = 2242) showed EMs had no impact on compliance (82 vs. 82%, group A vs. B), compliance with initial AI (82 vs. 81%) or persistence (90 vs. 88%), confirming the 1-year interim analysis (n = 2567). Of the 2082 patients considered compliant at 1 year, 77% remained compliant at 2 years. Discontinuations (9%) were mainly attributed to AI-related side effects (68% of discontinuations). Exploratory analyses suggest a relationship between patient characteristics and compliance behaviors. CONCLUSION: EMs do not improve compliance in this patient population. Compliance and persistence are complex end points influenced by multiple variables. Side effects were the main reasons for discontinuations.
Entities:
Keywords:
adherence; anastrozole; aromatase inhibitor; breast cancer; compliance; letrozole; persistence
Authors: Shoshana M Rosenberg; Keith J Petrie; Annette L Stanton; Lan Ngo; Emma Finnerty; Ann H Partridge Journal: J Natl Cancer Inst Date: 2020-05-01 Impact factor: 13.506
Authors: Thu Ha Dang; Abdur Rahim Mohammad Forkan; Nilmini Wickramasinghe; Prem Prakash Jayaraman; Marliese Alexander; Kate Burbury; Penelope Schofield Journal: JMIR Cancer Date: 2022-04-27
Authors: Ekim Ekinci; Salima Nathoo; Thushara Korattyil; Aisha Vadhariya; Hanna A Zaghloul; Polly A Niravath; Susan M Abughosh; Meghana V Trivedi Journal: J Cancer Surviv Date: 2018-02-02 Impact factor: 4.442
Authors: Sue P Heiney; Pearman D Parker; Tisha M Felder; Swann Arp Adams; Omonefe O Omofuma; Jennifer M Hulett Journal: Breast Cancer Res Treat Date: 2018-11-01 Impact factor: 4.872
Authors: Dawn L Hershman; Joseph M Unger; Grace Clarke Hillyer; Anna Moseley; Kathryn B Arnold; Shaker R Dakhil; Benjamin T Esparaz; Ming C Kuan; Mark L Graham; Douglas M Lackowski; William J Edenfield; Zoneddy R Dayao; N Lynn Henry; Julie R Gralow; Scott D Ramsey; Alfred I Neugut Journal: J Clin Oncol Date: 2020-05-05 Impact factor: 50.717
Authors: Andrew J Paladino; Janeane N Anderson; Rebecca A Krukowski; Teresa Waters; Mehmet Kocak; Carolyn Graff; Ryan Blue; Tameka N Jones; Joanne Buzaglo; Gregory Vidal; Lee Schwartzberg; Ilana Graetz Journal: BMC Health Serv Res Date: 2019-12-19 Impact factor: 2.655